Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04772885 · ClinicalTrials.gov registry record · Phase 1
A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)
A Phase 1 study, sponsored by Kymera Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 154
- Enrollment target
NCT04772885 is a Phase 1 study that has completed, run by Kymera Therapeutics. The registered enrollment target is 154 participants.
The verdict
NCT04772885, a Phase 1 study, has completed, sponsored by Kymera Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 154 participants
- Enrollment target
Study Summary
KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pharmacodynamics (PK/PD) of a single ascending dose and multiple ascending doses of KT-474 in healthy volunteers and patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS). The effects of food on the absorption of KT-474 will also be evaluated in healthy volunteers.
Interventions
- DRUG KT-474/Placebo
- DRUG KT-474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 154 participants |
| Start Date | 2021-02-23 |
| Est. Completion | 2022-10-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04772885
The ClinicalTrials.gov registry entry for NCT04772885 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which KT-474/Placebo is the first listed.
NCT04772885 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04772885 about?
NCT04772885 is a clinical study titled "A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)". KT-474 is an oral heterobifunctional small molecule IRAK4 degrader being developed for the treatment of interleukin-1 receptor (IL-1R)/toll-like receptor (TLR)-driven immune-inflammatory diseases. This first-in-human (FIH) study will characterize the safety, tolerability and the pharmacokinetics/pha...
What is the current status of trial NCT04772885?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2021-02-23. Estimated completion is 2022-10-20.
What interventions are being tested in trial NCT04772885?
The interventions under investigation include: KT-474/Placebo (DRUG), KT-474 (DRUG).
Who is sponsoring clinical trial NCT04772885?
This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.